Home arrow Cancer of Penis arrow Causes of Breast Cancer Friday, 21 November 2008



 
Slick RSS
MedicineNet Cancer General
MedicineNet Cancer General
MedicineNet Logo
MedicineNet Depression General
MedicineNet Depression General
MedicineNet Logo
Cancer / Oncology News From Medical News Today
Latest Cancer / Oncology News From Medical News Today.
  • Randomized Phase 2 Study Of IMC-A12 For HER2-Expressing Advanced Breast Cancer Commences Patient Enrollment
    ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that its disease-directed randomized Phase 2 clinical trial of IMC-A12 in patients with previously treated HER2-expressing locally advanced or metastatic breast cancer has commenced patient enrollment. IMC-A12 is ImClone's fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody.
  • GenVec Announces Interim Survival Data In Pivotal Trial Of TNFerade™ In Locally Advanced Pancreatic Cancer
    GenVec, Inc. (Nasdaq:GNVC) announced today top-line results of an interim analysis from its ongoing Phase III Pancreatic Cancer Clinical Trial with TNFerade™ (PACT) in patients with locally advanced pancreatic cancer. This interim analysis of overall survival, conducted after the 92nd death (one-third of total expected events), was designed to determine whether the study should continue and took place in the time frame originally estimated.
  • Bovie Medical Corporation Announces FDA 510(K) Clearance To Market SEER Tissue Resection Device
    Bovie Medical Corporation (the "Company") (NYSE Alternext US: BVX), a manufacturer and marketer of electrosurgical products, today announced the Company received 510(k) clearance from the Food and Drug Administration (FDA) to market its SEER tissue resection device intended for initial use in liver oncology surgery. The SEER device uses conductive sintered steel as an electrode for radio frequency (RF) for cutting and coagulation.
  • Relapsed Ovarian Cancer - Submitted New Drug Application To FDA For Trabectedin
    PharmaMar announced today that Ortho Biotech Products, L.P. has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for trabectedin when administered in combination with DOXIL® (pegylated liposomal doxorubicin) for the treatment of women with relapsed ovarian cancer (ROC). If approved, trabectedin combined with DOXIL® will provide a new, non-platinum treatment option for these patients in the United States.
  • Higher Risk Of Certain Cancers Being Recorded In HIV-Positive People
    Physicians in the U.S. are reporting a higher risk for certain types of cancers -- such as liver, head, neck and lung -- in people living with HIV/AIDS, raising concerns that a cancer epidemic is imminent in the population, the Baltimore Sun reports. According to the Sun, Meredith Shiels, a doctoral candidate at the